Q-omics provides the consensus-scored SELENOS profile across patient tissues and cancer cell-line models. SELENOS expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SELENOS is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, SELENOS protein abundance shows 27,180 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, HNSC, and GBM as cancer lineages where SELENOS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SELENOS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SELENOS survival associations across molecular data types. SELENOS RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SELENOS RNA expression–survival associations across cancer types. High SELENOS expression shows unfavorable associations in UVM, KICH, ACC, HNSC and CESC, but favorable associations in UCEC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SELENOS RNA expression.
This table summarizes SELENOS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 12. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SELENOS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SELENOS shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRC, LIHC, BLCA and BRCA. The HNSC box plot shows higher SELENOS RNA expression in tumor versus normal tissue (log2 FC = +0.705, t-test p < 0.001).
This table shows molecular features associated with SELENOS in patient tissues and cancer cell lines. In patient samples, SELENOS shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SELENOS RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
